<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-050897</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Bupropion use for smoking cessation in HIV-infected patients receiving antiretroviral therapy</dc:title>
<dc:description xml:lang="en">Smoking is the most important modifiable cardiovascular risk factor. Bupropion administration is an effective method to achieve smoking cessation (SC), but the drug is metabolized by the cytochrome P450 enzyme system and this might cause interactions with antiretroviral drugs. We present a prospective study of bupropion SC therapy in HIV-positive patients under antiretroviral treatment. A total of 21 patients were studied; 38% of them stopped smoking for more than one year. No clinically significant drug interactions were found. Bupropion SC therapy was effective in HIV-positive patients and did not cause significant clinical interactions with antiretroviral drugs (AU)</dc:description>
<dc:creator>Soler, Anna</dc:creator>
<dc:creator>Ribell-Bachs, Mónica</dc:creator>
<dc:creator>García-Rodríguez, Pedro</dc:creator>
<dc:creator>Deig-Comerma, Elisabet</dc:creator>
<dc:creator>Pedrol-Clotet, Enric</dc:creator>
<dc:creator>Vidal-Castell, Inmaculada</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El tabaquismo es el factor de riesgo cardiovascular modificable más importante. El bupropión es el método de deshabituación tabáquica (DT) más eficaz, pero se metaboliza por el citocromo P-450 y podría provocar interacciones con los antirretrovirales. Presentamos un estudio prospectivo de DT con bupropión en pacientes VIH1 en tratamiento antirretroviral. Se incluyeron 21 pacientes. El 38% seguían sin fumar al año. No se encontraron interacciones clínicamente significativas. La DT con bupropión es efectiva y no ha provocado interacciones clínicamente significativas con los antirretrovirales (AU)</dc:description>
<dc:source>Enferm Infecc Microbiol Clin;24(8): 509-511, oct. 2006.</dc:source>
<dc:identifier>ibc-050897</dc:identifier>
<dc:title xml:lang="es">Uso de bupropión en la deshabituación tabáquica en pacientes infectados por el VIH en tratamiento antirretroviral</dc:title>
<dc:subject>^d30220^s22079</dc:subject>
<dc:subject>^d24718</dc:subject>
<dc:subject>^d38332^s22079</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29815^s22045</dc:subject>
<dc:subject>^d23925^s22057</dc:subject>
<dc:subject>^d4409</dc:subject>
<dc:type>article</dc:type>
<dc:date>200610</dc:date>
</metadata>
</record>
</ibecs-document>
